• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Perspective Therapeutics, Inc.

    < Previous 1 2 Next >
    News headline image
    Perspective Therapeutics to Participate in Upcoming December Conferences
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate in Upcoming November Conferences
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate in Upcoming September Conferences
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate in Upcoming May Investor Conferences
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate in Upcoming April Investor Conferences
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Present at Upcoming March Investor Conferences
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate in Upcoming February Investor Conferences
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
    From Perspective Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.